## **CLAIM LISTING**

Claim 1 (Currently Amended): A pharmaceutical composition <u>for preventing, treating or managing one or more dermatological skin conditions</u> comprising a therapeutically effective amount of tetrasilver tetroxide, or a pharmaceutically acceptable derivative thereof, substantially free of added persulfate, <u>wherein the pharmaceutical composition further comprises a carrier medium that</u> adheres to skin.

Claim 2 (Currently Amended): The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is from about 50 ppm to 500,000 ppm.

Claim 3 (Currently Amended): The pharmaceutical composition of claim 1, wherein the therapeutically effective amount is from about 400 ppm to 100,000 ppm.

Claim 4 (Cancelled)

ť,

Claim 5 (Currently Amended): The pharmaceutical composition of claim [[4]] 1, adapted for topical administration and wherein the carrier comprises petroleum jelly.

Claim 6 (Currently Amended): The pharmaceutical composition of claim [[4]] 1, adapted for topical administration and further comprising a thixotropic agent sufficient to increase adherence of the composition to skin without excessive runoff.

USSN 10/630,737 Express Mail Receipt No. EV 436813855 US Claim 7 (Currently Amended): The pharmaceutical composition of claim 1, in the form of

further comprising a powder or a plurality of powder crystals or granules.

Claim 8 (Currently Amended): A method for preventing, treating, or managing one or more

dermatological skin diseases in a patient's skin, which comprises administering tetrasilver tetroxide,

or a pharmaceutically acceptable derivative thereof, which is substantially free of added persulfate, to

the skin in an amount and for a period of time which is therapeutically effective to treat such

condition(s), wherein the pharmaceutical composition further comprises a carrier medium that

adheres to skin.

₽,

Claim 9 (Currently Amended): The method of claim 8, further comprising a carrier medium

in which the tetrasilver tetroxide, or a derivative thereof, is dispersed, wherein the therapeutically

effective amount is from about 50 ppm to 500,000 ppm, based on the weight of the carrier medium.

Claim 10 (Original): The method of claim 9, wherein the carrier medium comprises

petroleum jelly.

Claim 11 (Currently Amended): The method of claim 8, wherein the tetrasilver tetroxide, or a

pharmaceutically acceptable derivative thereof, is administered in the form of a powder.

Claim 12 (Original): The method of claim 9, wherein the therapeutically effective amount is

from about 400 ppm to 100,000 ppm.

USSN 10/630,737 Express Mail Receipt No. EV 436813855 US 3

. . .

Claim 13 (Currently Amended): The method of claim 9, wherein the administering is topical,

<del>parenteral,</del> or transdermal.

ď,

Claim 14 (Original): The method of claim 13, wherein the composition is topically

administered directly to the skin.

Claim 15 (Original): The method of claim 14, wherein the tetrasilver tetroxide composition,

or a pharmaceutically acceptable derivative thereof, further comprises a thixotropic agent sufficient

to increase adherence of the composition to the skin without excessive runoff.

Claim 16 (Original): The method of claim 14, wherein the skin disease is caused by a non-

pathogenic condition comprising one or more of an autoimmune condition, a circulatory condition,

or a neurological condition.

Claim 17 (Original): The method of claim 8, wherein the skin disease prevented, treated, or

managed comprises at least one of eczema, psoriasis, dermatitis, ulcers, shingles, rashes, bedsores,

cold sores, blisters, boils, herpes, acne, pimples, skin chafing, skin cracking, skin itch, skin peeling,

heat rashes, leprosy, dermal tuberculosis, and warts.

Claim 18 (Original): The method of claim 17 wherein the skin disease prevented, treated, or

managed is one or more of cold sores, herpes, shingles, acne, psoriasis, dermatitis, skin ulcers, heat

rashes, leprosy, dermal tuberculosis, or eczema.

USSN 10/630,737

4

Claim 19 (Original): The method of claim 18, wherein the disease is psoriasis, skin ulcers,

heat rashes, leprosy, dermal tuberculosis, or atopic dermatitis.

Claim 20 (Original): The method of claim 8, wherein silver tetroxide, or a pharmaceutically

acceptable derivative thereof, is completely free of added persulfate.

Claim 21 (Original): The method of claim 8, wherein the administering comprises application

of the tetrasilver tetroxide, or a pharmaceutically acceptable derivative thereof, to the skin at a

dosage level of about 10 mg to 500 mg per cm<sup>2</sup> of skin surface.

Claim 22 (Original): The method of claim 8, wherein the amount is insufficient to cause

adverse effects.

ř,

Claim 23 (Currently Amended): A method for preventing, treating, or managing one or more

non-pathogenic, dermatological skin conditions, which comprises administering tetrasilver tetroxide,

or a pharmaceutically acceptable derivative thereof, substantially free of added persulfate, to the skin

in an amount and for a period of time which is therapeutically effective to treat such condition(s).

Claim 24 (Original): The method of claim 23, wherein the non-pathogenic, dermatological

skin condition comprises an autoimmune disorder, a neurological condition, a circulatory condition,

or a combination thereof.

USSN 10/630,737 Express Mail Receipt No. EV 436813855 US 5